Since 1973, Northwestern University has been a funded member of the Eastern Cooperative Oncology Group (ECOG). Through the years, the University has consistently offered its resources and investigator commitment to both the scientific development of ECOG and to the accrual of patients to ECOG clinical trials and ancillary studies. Northwestern's Robert H. Lurie Comprehensive Cancer Center provides the essential structural support for the University's ECOG program including its affiliated institutions (Cooperative Group Outreach Program [CGOP]). The Cancer Center successfully maintained its NCI Core Grant funding (P30 CA060553) and is a NCI Comprehensive Cancer Center. Furthermore, the Cancer Center has continued to integrate its clinical and laboratory science programs into a well-defined structure which provides important shared resources for Cancer Center members to support ECOG activity (e.g., Clinical Research Office, Serum and Tissue Banks, hematopathology, etc.) Al B. Benson III M.D., F.A.C.P. continues his role as Principal Investigator for Northwestern's ECOG grant. Both physicians maintain leadership roles within the Cancer Center resulting in enhanced integration of ECOG and Cancer Center activity. Northwestern's commitment to ECOG is exemplified by its consistent entry of new patients to ECOG trials with a substantial number of cases in follow-up each year. In addition, Northwestern investigators continue to chair numerous ECOG clinical trials and hold a number of key leadership positions within ECOG which include: Gl Committee chair (Benson), Data Monitoring Committee chair (Benson), elected Nominating Committee member (Benson), Gl Steering Committee to Rectal and Cancer Task Force (Benson), ECOG Member NCI Hepatobiliary Task Force (Mulcahy), Leukemia Committee chair (Tallman), Oncology Nursing Committee chair (O'Brien), Lymphoma Committee co-chair (Gordon) Patient Outcomes ans Survivorship Committee Chair (Cella, Wagner), Genito-Urinary Pathology Co-Chair (Guang Yu Yang) and the Pathology Coordinating Office-Reference Laboraotory (Ximing Yang). Since 2004, Northwestern investigators have authored or co-authored 112 publications and 98 abstracts and accrued 1421 patients (451 main /970 affiliates) with 1927 patients (460 main /1467 affiliates) in follow-up.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Tevaarwerk, Amye J; Lee, Ju-Whei; Terhaar, Abigail et al. (2016) Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer 122:438-46
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Langer, Corey J; Socinski, Mark A; Patel, Jyoti D et al. (2016) Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol 39:441-7
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Ganzel, Chezi; Manola, Judith; Douer, Dan et al. (2016) Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. J Clin Oncol 34:3544-3553
Kleinberg, Lawrence R; Catalano, Paul J; Forastiere, Arlene A et al. (2016) Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel/Cisplatin/Radiation Therapy (RT) or Irinotecan/Cisplatin/RT in Esophageal Adenocarcinoma: Long-Term Outcom Int J Radiat Oncol Biol Phys 94:738-46
Diefenbach, Catherine S; Li, Hailun; Hong, Fangxin et al. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-8
Lewis, Mark A; Zhao, Fengmin; Jones, Desiree et al. (2015) Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage 49:1016-24

Showing the most recent 10 out of 150 publications